Concerns & Risks -- 7/10
Favorable risk profile for a quality franchise. MCK clears the two highest-weight criteria cleanly --
effectively zero China exposure and a valuation below the peer average (~17.3x forward P/E vs ~19.2x
for Cencora/Cardinal Health). Catalysts are genuine but skew gradual/compounding rather than a single
dated near-term event. The cap on the score is a real and persistent regulatory overhang -- the 4th
Circuit's reopening of a $2.5B West Virginia opioid suit plus ongoing 340B/IRA/Medicaid/tariff noise --
alongside an FY2027 FCF guide that dips below FY2026 actual.
Weight: 15%
Valuation
Below Peers
~17.3x FY27 P/E vs ~19.2x peer avg
~2 turns cheap
China Exposure
~0%
~85% US/NA pharma distribution
Clears the bar
Regulatory
Overhang
Reopened $2.5B WV opioid suit
Caps the score
FY27 FCF Guide
Steps Down
$4.5-4.9B vs $5.41B FY26 actual
Yellow flag
Valuation -- Forward P/E (primary metric)
| Metric | FY+1 (FY2027) Estimate | Multiple | Peer Avg |
|---|---|---|---|
| Adj EPS (FY27 guide mid) | $44.20 (+12-14% YoY) | ~17.3x | ~19.2x |
| — Cencora (COR) fwd P/E | — | — | ~19.8x |
| — Cardinal Health (CAH) fwd P/E | — | — | ~18.6x |
| EV/EBITDA (TTM, secondary) | — | 13.45x | Mid-teens |
MCK trades ~2 turns below the peer average on forward P/E.
~17.3x FY2027 EPS versus a Cencora/Cardinal Health average of ~19.2x -- a discount despite MCK
being the scaled #1 in the oligopoly with the strongest tech-enabled services mix (RxTS) and the
highest ROIC (~31%). The FY2027 EPS guide of $43.80-$44.60 (+12-14% YoY) is supported by a fresh
+$5B buyback authorization. EV/Sales is meaningless at ~0.23x for a pass-through distribution model.
China / Import Exposure
Direct China revenue ~0%. Revenue is ~85% US/NA pharma
distribution plus Canada. China sourcing risk is low -- generics are sourced via NorthStar with no
fixed capital in any single country and a supply chain diversified post-COVID. Management states
tariffs are not expected to be material and are already in guidance under the pass-through model.
Clears the "no China" bar comfortably.
Key catalysts
| # | Catalyst | Timing | Read |
|---|---|---|---|
| 1 | Oncology Provider-Network M&A | Ongoing (active funnel) | Fastest grower (+31% FY26); compounding accretion, timing lumpy |
| 2 | Medical-Surgical Separation | Multi-quarter (H2 2027) | Sharpens distribution mix; execution catalyst |
| 3 | Biosimilar Adoption | In progress | STELARA / retina-PRISM / Part B & D -- margin tailwind in the oncology channel |
| 4 | GLP-1 / Specialty Volume | Ongoing | Above-GDP volume driver for the core distribution book |
| 5 | +$5B Buyback | FY2027 | Direct support for the +12-14% EPS algorithm |
Catalysts are real but mostly gradual/compounding rather than a single dated near-term event -- hence not a clean 10.
Regulatory / political risk
| # | Risk | Severity | Detail |
|---|---|---|---|
| 1 | Opioid Litigation | HIGH | National settlement largely behind, but the 4th Circuit reopened a $2.5B West Virginia suit (2025) -- residual tail risk. |
| 2 | Pharma Tariffs (Apr 2026 proclamation) | LOW-MEDIUM | Management: immaterial -- pass-through model plus diversified sourcing; generics exempt. |
| 3 | 340B / IRA / Medicaid / DSCSA | MEDIUM | Evolving structural overhangs across the channel. |
| 4 | Drug Pricing / MFN | MEDIUM | Fee-based margin partially insulated, but headline risk persists. |
This persistent regulatory overhang is the main thing keeping the
score out of the 8-10 zone. The opioid tail (reopened $2.5B WV suit) plus 340B/IRA/tariff
noise create a recurring headline risk that caps the multiple even though the fee-based model is
partially insulated on economics.
Bull case
| # | Factor | Detail |
|---|---|---|
| 1 | Cheap Oligopoly Leader | Scaled #1 in a GDP-plus-growing oligopoly, trading ~2 turns below peers on forward P/E with ~31% ROIC. |
| 2 | +12-14% Guided EPS Growth | FY2027 EPS guide $43.80-$44.60, backed by a fresh +$5B buyback authorization. |
| 3 | Oncology Compounding +31% | Fastest-growing segment; biosimilar and GLP-1 tailwinds layered on top. |
| 4 | Clean Balance Sheet | Net debt/EBITDA 0.66x; capital-light, cash-generative pass-through model. |
| 5 | ~0% China, Tariff-Neutral | Effectively zero China exposure and a pass-through model that neutralizes tariffs. |
Bear case
| # | Factor | Detail |
|---|---|---|
| 1 | FY27 FCF Steps Down | FY2027 FCF guide ($4.5-4.9B) sits below FY2026 actual ($5.41B) despite +10% AOP -- a cash-conversion yellow flag. |
| 2 | Persistent Regulatory Overhang | Reopened $2.5B WV opioid suit plus 340B/IRA/tariff uncertainty cap the multiple. |
| 3 | Gradual Catalysts | Catalysts skew compounding rather than dated; oncology M&A timing is unpredictable. |
| 4 | Thin-Margin Volume Model | EV/Sales ~0.23x pass-through economics with limited core pricing power. |
| 5 | Med-Surg Separation Risk | The H2 2027 separation carries execution and stranded-cost risk. |
Score rationale
Score of 7/10 reflects a favorable risk/reward for a quality franchise, capped by a persistent regulatory tail.
Supports 7/10:
- Clears the two highest-weight criteria cleanly -- effectively zero China exposure and valuation below peers (~17.3x forward P/E vs ~19.2x)
- Clean balance sheet (net debt/EBITDA 0.66x), ~31% ROIC, +12-14% guided EPS growth with a +$5B buyback
- Genuine catalysts: oncology M&A (+31% grower), Med-Surg separation, biosimilar adoption, GLP-1 volume
Held to 7 (not 8-10):
- Persistent regulatory overhang -- 4th Circuit reopened a $2.5B WV opioid suit, plus 340B/IRA/Medicaid/DSCSA/tariff/MFN noise
- FY2027 FCF guide ($4.5-4.9B) dips below FY2026 actual ($5.41B) -- a cash-conversion yellow flag
- Catalysts skew gradual/compounding rather than a single dated near-term event
Net: a quality oligopoly leader at a below-peer multiple with effectively no China exposure, held out of the top band by a real and recurring regulatory tail and a softer FY2027 cash-conversion guide.
Data sourced from Daloopa (company_id: 482). Peer multiples and regulatory backdrop via web search; quote/ratios via FMP.